CA2603763A1 - 5-methyl-1-(substituted phenyl)-2-(1h)-pyridone in the manufacture of medicaments for treating fibrosis in organ or tissues - Google Patents

5-methyl-1-(substituted phenyl)-2-(1h)-pyridone in the manufacture of medicaments for treating fibrosis in organ or tissues Download PDF

Info

Publication number
CA2603763A1
CA2603763A1 CA002603763A CA2603763A CA2603763A1 CA 2603763 A1 CA2603763 A1 CA 2603763A1 CA 002603763 A CA002603763 A CA 002603763A CA 2603763 A CA2603763 A CA 2603763A CA 2603763 A1 CA2603763 A1 CA 2603763A1
Authority
CA
Canada
Prior art keywords
methyl
pyridone
akf
fibrosis
compounds
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002603763A
Other languages
English (en)
French (fr)
Inventor
Lijian Tao
Gaoyun Hu
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Xiangya Hospital of Central South University
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2603763A1 publication Critical patent/CA2603763A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4412—Non condensed pyridines; Hydrogenated derivatives thereof having oxo groups directly attached to the heterocyclic ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4402—Non condensed pyridines; Hydrogenated derivatives thereof only substituted in position 2, e.g. pheniramine, bisacodyl
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4418—Non condensed pyridines; Hydrogenated derivatives thereof having a carbocyclic group directly attached to the heterocyclic ring, e.g. cyproheptadine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/62—Oxygen or sulfur atoms
    • C07D213/63—One oxygen atom
    • C07D213/64—One oxygen atom attached in position 2 or 6
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Cardiology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Neurology (AREA)
  • Urology & Nephrology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Hospice & Palliative Care (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Psychiatry (AREA)
  • Pulmonology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Dermatology (AREA)
  • Vascular Medicine (AREA)
  • Rheumatology (AREA)
  • Pyridine Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
CA002603763A 2005-04-13 2006-04-11 5-methyl-1-(substituted phenyl)-2-(1h)-pyridone in the manufacture of medicaments for treating fibrosis in organ or tissues Abandoned CA2603763A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CNA2005100314457A CN1846699A (zh) 2005-04-13 2005-04-13 1－(取代苯基)－5－甲基－2－(1h) 吡啶酮(i)化合物用于制备抗除肾间质纤维化外其他器官纤维化或组织纤维化药物的应用
CN200510031445.7 2005-04-13
PCT/CN2006/000651 WO2006108354A1 (fr) 2005-04-13 2006-04-11 5-méthyl-2-(1h)-pyridone substituée en 1 par un groupement phényle dans la fabrication de médicaments pour le traitement de la fibrose d'organes ou de tissus

Publications (1)

Publication Number Publication Date
CA2603763A1 true CA2603763A1 (en) 2006-10-19

Family

ID=37076581

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002603763A Abandoned CA2603763A1 (en) 2005-04-13 2006-04-11 5-methyl-1-(substituted phenyl)-2-(1h)-pyridone in the manufacture of medicaments for treating fibrosis in organ or tissues

Country Status (10)

Country Link
US (3) US20090005424A9 (enExample)
EP (1) EP1878428A4 (enExample)
JP (1) JP2008535871A (enExample)
KR (1) KR20080018857A (enExample)
CN (2) CN1846699A (enExample)
AU (1) AU2006233433A1 (enExample)
CA (1) CA2603763A1 (enExample)
RU (1) RU2007141892A (enExample)
TW (1) TW200808315A (enExample)
WO (1) WO2006108354A1 (enExample)

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8304413B2 (en) 2008-06-03 2012-11-06 Intermune, Inc. Compounds and methods for treating inflammatory and fibrotic disorders
US8741936B2 (en) 2005-05-10 2014-06-03 Intermune, Inc. Method of modulating stress-activated protein kinase system
US9359379B2 (en) 2012-10-02 2016-06-07 Intermune, Inc. Anti-fibrotic pyridinones
US10233195B2 (en) 2014-04-02 2019-03-19 Intermune, Inc. Anti-fibrotic pyridinones

Families Citing this family (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10569792B2 (en) 2006-03-20 2020-02-25 General Electric Company Vehicle control system and method
US10308265B2 (en) 2006-03-20 2019-06-04 Ge Global Sourcing Llc Vehicle control system and method
US9733625B2 (en) 2006-03-20 2017-08-15 General Electric Company Trip optimization system and method for a train
US8924049B2 (en) 2003-01-06 2014-12-30 General Electric Company System and method for controlling movement of vehicles
JP4614884B2 (ja) 2003-11-14 2011-01-19 シャンハイ ゲノミックス インク ピリドンの誘導体とその使用
CN1846699A (zh) * 2005-04-13 2006-10-18 中南大学湘雅医院 1－(取代苯基)－5－甲基－2－(1h) 吡啶酮(i)化合物用于制备抗除肾间质纤维化外其他器官纤维化或组织纤维化药物的应用
US9689681B2 (en) 2014-08-12 2017-06-27 General Electric Company System and method for vehicle operation
US8370006B2 (en) 2006-03-20 2013-02-05 General Electric Company Method and apparatus for optimizing a train trip using signal information
US8126601B2 (en) 2006-03-20 2012-02-28 General Electric Company System and method for predicting a vehicle route using a route network database
US9156477B2 (en) 2006-03-20 2015-10-13 General Electric Company Control system and method for remotely isolating powered units in a vehicle system
US8290645B2 (en) 2006-03-20 2012-10-16 General Electric Company Method and computer software code for determining a mission plan for a powered system when a desired mission parameter appears unobtainable
CN101652138B (zh) * 2007-09-19 2011-07-06 中南大学 1-取代芳基-2（1h）-吡啶酮化合物的新医药用途
CN101235013A (zh) 2008-03-10 2008-08-06 广东东阳光药业有限公司 结晶型1-（3-氟苯基）-5-甲基-2-（1h）吡啶酮、其制备方法、及其组合物和应用
US20100099719A1 (en) * 2008-10-21 2010-04-22 Dierepharma, Inc. Composition and method for treating proteinuria
US7566729B1 (en) 2008-11-10 2009-07-28 Intermune, Inc. Modifying pirfenidone treatment for patients with atypical liver function
US7635707B1 (en) 2008-11-10 2009-12-22 Intermune, Inc. Pirfenidone treatment for patients with atypical liver function
US8016980B2 (en) 2008-11-25 2011-09-13 Dixie Consumer Products Llc Paper products
US9834237B2 (en) 2012-11-21 2017-12-05 General Electric Company Route examining system and method
CN101921225B (zh) * 2009-06-11 2013-04-03 北京凯得尔森生物技术有限公司 吡啡尼酮类化合物、其制备方法和应用
US8084475B2 (en) 2009-12-04 2011-12-27 Intermune, Inc. Pirfenidone therapy and inducers of cytochrome P450
US7816383B1 (en) 2009-12-04 2010-10-19 Intermune, Inc. Methods of administering pirfenidone therapy
JP6021117B2 (ja) 2011-01-31 2016-11-02 ジェノア ファーマシューティカルズ，インク． エアロゾルのピルフェニドンおよびピリドンアナログの化合物、および、その使用
US10105356B2 (en) 2011-01-31 2018-10-23 Avalyn Pharma Inc. Aerosol pirfenidone and pyridone analog compounds and uses thereof
MX2015000830A (es) 2012-07-18 2015-10-26 Sunshine Lake Pharma Co Ltd Derivados heterociclicos nitrogenosos y su aplicacion en farmacos.
CA2819967C (en) 2012-08-31 2016-03-22 Intermune, Inc. Use of pirfenidone concomitantly with ciprofloxacin
US9669851B2 (en) 2012-11-21 2017-06-06 General Electric Company Route examination system and method
US9682716B2 (en) 2012-11-21 2017-06-20 General Electric Company Route examining system and method
US9902712B2 (en) 2013-12-19 2018-02-27 Sunshine Lake Pharma Co., Ltd. Nitrogenous heterocyclic derivatives and their application in drugs
EP4491180A1 (en) 2014-01-10 2025-01-15 Avalyn Pharma Inc. Aerosol pirfenidone and pyridone analog compounds and uses thereof
EP3117220B1 (en) * 2014-03-12 2020-07-08 Icahn School of Medicine at Mount Sinai Method for identifying kidney allograft recipients at risk for chronic injury
WO2015200887A2 (en) 2014-06-26 2015-12-30 Icahn School Of Medicine At Mount Sinai Method for diagnosing subclinical and clinical acute rejection by analysis of predictive gene sets
EP3194025A4 (en) * 2014-09-18 2018-05-23 Rush University Medical Center Methods for preventing or treating osteoarthritis
DE102015217418A1 (de) 2015-09-11 2017-03-16 Mühlbauer Technology Gmbh Radikalisch polymerisierbares Dentalmaterial
EP3308765B1 (de) 2016-10-17 2022-07-13 Mühlbauer Technology GmbH Radikalisch polymerisierbare verbindung
WO2019011163A1 (en) * 2017-07-14 2019-01-17 Sunshine Lake Pharma Co., Ltd. PROCESS FOR THE PREPARATION OF A PYRIMIDONE COMPOUND
WO2019204267A1 (en) 2018-04-16 2019-10-24 Icahn School Of Medicine At Mount Sinai Method and kits for prediction of acute rejection and renal allograft loss using pre-transplant transcriptomic signatures in recipient blood
CN113274389B (zh) * 2021-07-09 2022-11-08 中南大学 氟非尼酮在制备治疗急性肺损伤药物中的应用
CN113456636A (zh) * 2021-07-09 2021-10-01 中南大学 一种氟非尼酮在制备急性肝损伤药物中的应用
CN114716365B (zh) * 2022-01-04 2024-03-01 大连理工大学 一类n-取代苯基-2-吡啶酮化合物或其可药用盐在治疗肺纤维化中的应用
WO2024235145A1 (zh) * 2023-05-12 2024-11-21 大连理工大学 一类n-取代苯基-2-吡啶酮及内过氧化物的制备和应用
CN118526493A (zh) * 2023-10-30 2024-08-23 大连理工大学 一类n-取代苯基-2-吡啶酮化合物在治疗癌症和缓解纤维化中的应用
CN120053452B (zh) * 2023-11-30 2025-12-05 长沙晶易医药科技股份有限公司 一种2,4-二取代-5-氟嘧啶衍生物的新用途

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4042699A (en) 1972-12-18 1977-08-16 Affiliated Medical Research, Inc. Method for reducing serum glucose levels
US4052509A (en) 1972-12-18 1977-10-04 Affiliated Medical Research, Inc. Method for reducing serum uric acid levels
CA1049411A (en) 1972-12-18 1979-02-27 Affiliated Medical Research N-substituted pyridone and general method for preparing pyridones
US3839346A (en) 1972-12-18 1974-10-01 Affiliated Med Res N-substituted pyridone and general method for preparing pyridones
JPH02215719A (ja) 1989-02-15 1990-08-28 Yamauchi Akitomo 線維化病変組織の修復並びに線維化病変の阻止剤
US5716632A (en) 1989-11-22 1998-02-10 Margolin; Solomon B. Compositions and methods for reparation and prevention of fibrotic lesions
US5310562A (en) * 1989-11-22 1994-05-10 Margolin Solomon B Composition and method for reparation and prevention of fibrotic lesions
US5518729A (en) 1989-11-22 1996-05-21 Margolin; Solomon B. Compositions and methods for reparation and prevention of fibrotic lesions
CN2114190U (zh) 1992-01-09 1992-08-26 王刚 恒流一体化集成电源器件
US5716623A (en) * 1994-12-07 1998-02-10 Immunex Corporation Isolated Herpesvirus saimiri proteins that bind MHC Class II molecules
JP3496553B2 (ja) * 1998-08-07 2004-02-16 株式会社高尾 弾球遊技機
CN1218942C (zh) * 2002-06-11 2005-09-14 中南大学湘雅医学院 抗纤维化吡啶酮化合物及其生产工艺方法
CN1846699A (zh) * 2005-04-13 2006-10-18 中南大学湘雅医院 1－(取代苯基)－5－甲基－2－(1h) 吡啶酮(i)化合物用于制备抗除肾间质纤维化外其他器官纤维化或组织纤维化药物的应用

Cited By (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8741936B2 (en) 2005-05-10 2014-06-03 Intermune, Inc. Method of modulating stress-activated protein kinase system
US9527816B2 (en) 2005-05-10 2016-12-27 Intermune, Inc. Method of modulating stress-activated protein kinase system
US8304413B2 (en) 2008-06-03 2012-11-06 Intermune, Inc. Compounds and methods for treating inflammatory and fibrotic disorders
US8969347B2 (en) 2008-06-03 2015-03-03 Intermune, Inc. Compounds and methods for treating inflammatory and fibrotic disorders
US9290450B2 (en) 2008-06-03 2016-03-22 Intermune, Inc. Compounds and methods for treating inflammatory and fibrotic disorders
USRE47142E1 (en) 2008-06-03 2018-11-27 Intermune, Inc. Compounds and methods for treating inflammatory and fibrotic disorders
US9359379B2 (en) 2012-10-02 2016-06-07 Intermune, Inc. Anti-fibrotic pyridinones
US9675593B2 (en) 2012-10-02 2017-06-13 Intermune, Inc. Anti-fibrotic pyridinones
US10376497B2 (en) 2012-10-02 2019-08-13 Intermune, Inc. Anti-fibrotic pyridinones
US10898474B2 (en) 2012-10-02 2021-01-26 Intermune, Inc. Anti-fibrotic pyridinones
US10233195B2 (en) 2014-04-02 2019-03-19 Intermune, Inc. Anti-fibrotic pyridinones
US10544161B2 (en) 2014-04-02 2020-01-28 Intermune, Inc. Anti-fibrotic pyridinones

Also Published As

Publication number Publication date
RU2007141892A (ru) 2009-05-20
EP1878428A4 (en) 2008-09-03
WO2006108354A1 (fr) 2006-10-19
US20090005424A9 (en) 2009-01-01
TW200808315A (en) 2008-02-16
CN1953749B (zh) 2010-04-14
US20080319027A1 (en) 2008-12-25
CN1846699A (zh) 2006-10-18
AU2006233433A1 (en) 2006-10-19
CN1953749A (zh) 2007-04-25
KR20080018857A (ko) 2008-02-28
US20070203203A1 (en) 2007-08-30
JP2008535871A (ja) 2008-09-04
EP1878428A1 (en) 2008-01-16
US20090258911A1 (en) 2009-10-15

Similar Documents

Publication Publication Date Title
CA2603763A1 (en) 5-methyl-1-(substituted phenyl)-2-(1h)-pyridone in the manufacture of medicaments for treating fibrosis in organ or tissues
EP0980244B1 (en) Use of quinazoline compounds for the treatment of polycystic kidney disease
EP1940364B1 (en) Capsule formulation of pirfenidone and pharmaceutically acceptable excipients
US10322135B2 (en) Pharmaceutical composition comprising indole compound
US20130303543A1 (en) Protection of renal tissues from ischemia through inhibition of the proliferative kinases cdk4 and cdk6
JP6262225B2 (ja) オキサビシクロヘプタン類、および再灌流障害の治療のためのオキサビシクロヘプタン類
KR20140129030A (ko) 캔디다증 및 아스퍼질러스 감염을 치료하기 위한 화합물 및 방법
Deng et al. Synthesis and discovery of new compounds bearing coumarin scaffold for the treatment of pulmonary fibrosis
EP4234021B1 (en) Pharmaceutical composition comprising an adenosine derivative for use in the prevention or treatment of diabetic nephropathy
WO2003077832A2 (en) Dexanabinol and dexanabinol analogs regulate inflammation related genes
IL35098A (en) Pharmaceutical compositions containing mono-amides of phthalic and pyridine dicarboxylic acids
JP2008514636A (ja) サイトカイン活性の低分子モジュレーター
CN106466318A (zh) 1-杂环取代苄基吡啶酮类化合物在制备治疗糖尿病肾病药物中的应用
EP4252751B1 (en) Pharmaceutical composition for preventing or treating wound or scar, comprising benzbromarone
KR102676631B1 (ko) 과민성 방광의 예방 또는 치료용 약학적 조성물
Mathew et al. Antifilarial agents
JP4235000B2 (ja) 糸球体疾患治療剤
KR20050002109A (ko) 메톡시아크릴레이트계 화합물을 포함하는, 골다공증 예방또는 치료용 조성물
CN105555275B (zh) 含有dpp-iv抑制剂的用于预防和治疗肾脏疾病的组合物
CN120459090A (zh) 化合物ctu-b2r在制备治疗弓形虫病的药物中的应用
AU2013201986A1 (en) Capsule Formulation Of Pirfenidone And Pharmaceutically Acceptable Excipients
HK1166791B (en) Preparation of 1-(substituted benzyl)-5-trifluoromethyl-2-(1h)pyridone compounds and salts thereof and their applications
JP2003238408A (ja) 組織線維症の治療剤または予防剤
HK1025262B (en) Use of quinazoline compounds for the treatment of polycystic kidney disease
HK1117762B (en) Capsule formulation of pirfenidone and pharmaceutically acceptable excipients

Legal Events

Date Code Title Description
EEER Examination request
FZDE Discontinued